Results 21 to 30 of about 7,763 (163)

Artemether–lumefantrine treatment failure despite adequate lumefantrine day 7 concentration in a traveller with Plasmodium falciparum malaria after returning from Tanzania

Malaria Journal, 2012
Artemether-lumefantrine is currently first-line therapy of Plasmodium falciparum malaria in many countries. This report describes a treatment failure despite adequate drug concentrations in a traveller returning from sub-Saharan Africa.
Färnert Anna, Ursing Johan, Tolfvenstam Thomas, Rono Josea, Karlsson Lillemor, Sparrelid Elda, Lindegårdh Niklas   +6 more
doaj   +1 more source

Pyronaridine-artesunate granules versus artemether-lumefantrine crushed tablets in children with Plasmodium falciparum malaria: a randomized controlled trial

Malaria Journal, 2012
Background Children are most vulnerable to malaria. A pyronaridine-artesunate pediatric granule formulation is being developed for the treatment of uncomplicated Plasmodium falciparum malaria. Methods This phase III, multi-center, comparative, open-label,
Kayentao Kassoum, Doumbo Ogobara K, Pénali Louis K, Offianan André T, Bhatt Kirana M, Kimani Joshua, Tshefu Antoinette K, Kokolomami Jack HT, Ramharter Michael, de Salazar Pablo Martinez, Tiono Alfred B, Ouédraogo Alphonse, Bustos Maria Dorina G, Quicho Frederick, Borghini-Fuhrer Isabelle, Duparc Stephan, Shin Chang-Sik, Fleckenstein Lawrence   +17 more
doaj   +1 more source

Genome‐Guided Discovery of Antimalarial 4‐Amino‐2,4‐Pentadienoate‐Containing Cyclolipodepsipeptides

Angewandte Chemie, Volume 138, Issue 18, 27 April 2026.
Halogenated and glycosylated 4‐amino‐2,4‐pentadienoate‐containing cyclolipodepsipeptides (APD‐CLDs) exhibit potent antiplasmodial activity (IC50 = 25–161 nM) against drug‐sensitive and resistant Plasmodium falciparum strains. ABSTRACT 4‐Amino‐2,4‐pentadienoate‐containing cyclolipodepsipeptides (APD‐CLDs) represent a structurally distinctive family of ...
Hartono Candra, Xue‐Jiao Wang, Ka Diam Go, Li Feng, Miaomiao Cai, Guang‐Lei Ma, Clarissa Widyantoro, Lik Tong Tan, Zbynek Bozdech, Zhe Wang, Zhao‐Xun Liang   +10 more
wiley   +2 more sources

Developmental Toxicity Study for the Antimalarial Drug Combination Cabamiquine‐Pyronaridine Using a Translational Approach

Birth Defects Research, Volume 118, Issue 10, October 2026.
ABSTRACT Background The safety of pharmacological treatments during pregnancy is a significant concern, as many medications lack comprehensive reproductive safety data. This creates gaps in therapeutic options for pregnant women, particularly malaria, which poses serious risks to maternal and fetal health.
Wookyung Kim, Geum‐Sil Cho, Andreas Gado, Tobias Hyun Ho Baeurle, Habib Karimi, Filippo Venezia, Claude Oeuvray, Thomas Spangenberg, Sebastian G. Wicha, Claudia Demarta‐Gatsi   +9 more
wiley   +1 more source

Severe Plasmodium vivax Malaria Complicated by Secondary Hemophagocytic Lymphohistiocytosis, Disseminated Intravascular Coagulation, and Acute Pancreatitis: A Case Report

Clinical Case Reports, Volume 14, Issue 10, October 2026.
ABSTRACT Plasmodium vivax (P. vivax) malaria, once regarded as a comparatively benign infection, is increasingly recognized as a cause of severe, potentially life‐threatening multisystem disease. Concurrent secondary hemophagocytic lymphohistiocytosis (HLH), disseminated intravascular coagulation (DIC), and acute pancreatitis complicating P.
Tasnim Nafian, Md. Abul Kalam Azad, Khaled Mahbub Murshed, Kazi Ali Aftab, Rubayet Shahriar, Abdullah Al Faisal   +5 more
wiley   +1 more source

Usefulness of combined screening methods for rapid detection of falsified and/or substandard medicines in the absence of a confirmatory method

Malaria Journal, 2019
Background The influx of substandard and falsified medicines is a global public health challenge and its rapid detection is a key solution to the menace. This study used three screening methods and one confirmatory method for the quality assessment of 25
Kwabena Frimpong-Manso Opuni, Henry Nettey, Marvin Adjei Larbi, Salome Naa Amerley Amartey, Gifty Nti, Abraham Dzidonu, Patrick Owusu-Danso, Nicholas Amoah Owusu, Alexander Kwadwo Nyarko   +8 more
doaj   +1 more source

Malaria‐Associated Secondary Hematophagocytic Lymphohistocytosis—A Case Report and Comprehensive Literature Review (sHLH)

Clinical Case Reports, Volume 14, Issue 9, September 2026.
ABSTRACT Malaria‐associated secondary HLH, though rare, is often overlooked. Clinicians should maintain a high‐index of suspicion in travelers returning from malaria‐endemic regions who develop severe to rapidly worsening inflammatory illness, as early recognition is critical for survival.
Indresh Yadav, Sulav Kumar Jha, Sweta Singh, Dipesh Kumar Mandal, Saurav Jha   +4 more
wiley   +1 more source

Simultaneous Estimation of Artemether and Lumefantrine by RP-HPLC Method Development in Pharmaceutical Tablet Dosage Form

RGUHS Journal of Pharmaceutical Sciences
Background Artemether and Lumefantrine are widely used antimalarial agents whose simultaneous quantification in tablet formulations is essential for quality control.Objectives To develop and validate a simple accurate and robust ...
Lekhana A M, Paul Richards M, Vishwanath BA   +2 more
doaj   +1 more source

Prospective evaluation of artemether-lumefantrine for the treatment of non-falciparum and mixed-species malaria in Gabon

Malaria Journal, 2012
Background The recommendation of artemisinin combination therapy (ACT) as first-line treatment for uncomplicated falciparum malaria is supported by a plethora of high quality clinical trials.
Mombo-Ngoma Ghyslain, Kleine Christian, Basra Arti, Würbel Heike, Diop Daisy A, Capan Mesküre, Adegnika Ayola A, Kurth Florian, Mordmüller Benjamin, Joanny Fanny, Kremsner Peter G, Ramharter Michael, Bélard Sabine   +12 more
doaj   +1 more source

Monitoring of the Sensitivity In Vivo of Plasmodium falciparum to Artemether-Lumefantrine in Mali

Tropical Medicine and Infectious Disease, 2021
In Mali, since 2007, artemether-lumefantrine has been the first choice against uncomplicated malaria. Despite its effectiveness, a rapid selection of markers of resistance to partner drugs has been documented.
Modibo Diarra, Drissa Coulibaly, Amadou Tapily, Boureima Guindo, Koualy Sanogo, Diakalia Koné, Youssouf Koné, Karim Koné, Aboudramane Bathily, Oumar Yattara, Mahamadou A. Thera, Alassane Dicko, Abdoulaye A. Djimdé, Issaka Sagara   +13 more
doaj   +1 more source